Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 13/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 2/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.32 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1099015 | 0.90 | TRPM8 (0.31) | TRPM8 | |
| SCHEMBL1097914 | 0.87 | TRPM8 (0.43) | TRPM8HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL1098618 | 0.85 | TRPM8 (0.44) | TRPM8CMKLR1 | |
| SCHEMBL1098685 | 0.85 | TRPM8 (0.41) | TRPM8HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL1097814 | 0.84 | TRPM8 (0.40) | TRPM8HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL1098232 | 0.82 | TRPM8 (0.48) | TRPM8HTR2A | |
| SCHEMBL1097877 | 0.81 | RORC (0.37) | TRPM8HTR1ADRD2HTR2ACMKLR1 | |
| SCHEMBL1098574 | 0.80 | PSEN1 (0.33) | TRPM8TNKSTNKS2CMKLR1 | |
| SCHEMBL1099089 | 0.80 | TRPM8 (0.44) | TRPM8HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL1100161 | 0.79 | TRPM8 (0.67) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434711-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2016-09-06 | — | — | US | disclosed |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-23 | — | — | US | disclosed |
| CN-101801949-B | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA NV | 2014-09-24 | — | — | CN | disclosed |
| US-8809327-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-19 | — | — | US | disclosed |
| EP-2183239-B1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-22 | — | — | EP | disclosed |
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | BRANUM SHAWN T (US) | 2012-07-26 | — | — | US | disclosed |
| US-8153682-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-10 | — | — | US | disclosed |
| CN-101801949-A | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA NV | 2010-08-11 | — | — | CN | disclosed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | TRPM8 1/4885HTR1A 432/4885DRD2 2465/4885 |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | TRPM8 1/4885HTR1A 432/4885DRD2 2465/4885 |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | TRPM8 1/4885HTR1A 432/4885DRD2 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.